Opportunities and limitations of bone marrow biopsy and bone marrow FDG-PET in lymphoma

Hugo J A Adams; Rutger A J Nievelstein; Thomas C. Kwee

doi:10.1016/j.blre.2015.06.003

Opportunities and limitations of bone marrow biopsy and bone marrow FDG-PET in lymphoma

Hugo J A Adams^*
, Rutger A J Nievelstein
, Thomas C. Kwee

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Bone marrow involvement in lymphoma may have prognostic and therapeutic consequences. Bone marrow biopsy (BMB) is the established method for the evaluation of the bone marrow. ¹⁸F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) plays an important role in lymphoma staging, but its value in the assessment of the bone marrow and whether it can replace BMB is still a topic of debate and investigation. The purpose of this scientific communication is to provide an evidence-based overview about the opportunities and limitations of BMB and FDG-PET in the evaluation of the bone marrow in patients with lymphoma. This article first reviews the basic properties, opportunities and limitations of BMB and bone marrow FDG-PET, and then focuses on the clinical utility of BMB and bone marrow FDG-PET in three major lymphoma subtypes including Hodgkin lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma.

Original language	English
Pages (from-to)	417-425
Number of pages	9
Journal	Blood Reviews
Volume	29
Issue number	6
DOIs	https://doi.org/10.1016/j.blre.2015.06.003
Publication status	Published - Nov 2015

Keywords

Bone marrow
Diffuse large B-cell lymphoma
FDG-PET
Follicular lymphoma
Hodgkin lymphoma

Access to Document

10.1016/j.blre.2015.06.003

54-mainFinal published version, 366 KB

Cite this

@article{82656f998f5a4b20be22fede5e9e3793,

title = "Opportunities and limitations of bone marrow biopsy and bone marrow FDG-PET in lymphoma",

abstract = "Bone marrow involvement in lymphoma may have prognostic and therapeutic consequences. Bone marrow biopsy (BMB) is the established method for the evaluation of the bone marrow. 18F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) plays an important role in lymphoma staging, but its value in the assessment of the bone marrow and whether it can replace BMB is still a topic of debate and investigation. The purpose of this scientific communication is to provide an evidence-based overview about the opportunities and limitations of BMB and FDG-PET in the evaluation of the bone marrow in patients with lymphoma. This article first reviews the basic properties, opportunities and limitations of BMB and bone marrow FDG-PET, and then focuses on the clinical utility of BMB and bone marrow FDG-PET in three major lymphoma subtypes including Hodgkin lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma.",

keywords = "Bone marrow, Diffuse large B-cell lymphoma, FDG-PET, Follicular lymphoma, Hodgkin lymphoma",

author = "Adams, \{Hugo J A\} and Nievelstein, \{Rutger A J\} and Kwee, \{Thomas C.\}",

year = "2015",

month = nov,

doi = "10.1016/j.blre.2015.06.003",

language = "English",

volume = "29",

pages = "417--425",

journal = "Blood Reviews",

issn = "0268-960X",

publisher = "Churchill Livingstone",

number = "6",

}

TY - JOUR

T1 - Opportunities and limitations of bone marrow biopsy and bone marrow FDG-PET in lymphoma

AU - Adams, Hugo J A

AU - Nievelstein, Rutger A J

AU - Kwee, Thomas C.

PY - 2015/11

Y1 - 2015/11

N2 - Bone marrow involvement in lymphoma may have prognostic and therapeutic consequences. Bone marrow biopsy (BMB) is the established method for the evaluation of the bone marrow. 18F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) plays an important role in lymphoma staging, but its value in the assessment of the bone marrow and whether it can replace BMB is still a topic of debate and investigation. The purpose of this scientific communication is to provide an evidence-based overview about the opportunities and limitations of BMB and FDG-PET in the evaluation of the bone marrow in patients with lymphoma. This article first reviews the basic properties, opportunities and limitations of BMB and bone marrow FDG-PET, and then focuses on the clinical utility of BMB and bone marrow FDG-PET in three major lymphoma subtypes including Hodgkin lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma.

AB - Bone marrow involvement in lymphoma may have prognostic and therapeutic consequences. Bone marrow biopsy (BMB) is the established method for the evaluation of the bone marrow. 18F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) plays an important role in lymphoma staging, but its value in the assessment of the bone marrow and whether it can replace BMB is still a topic of debate and investigation. The purpose of this scientific communication is to provide an evidence-based overview about the opportunities and limitations of BMB and FDG-PET in the evaluation of the bone marrow in patients with lymphoma. This article first reviews the basic properties, opportunities and limitations of BMB and bone marrow FDG-PET, and then focuses on the clinical utility of BMB and bone marrow FDG-PET in three major lymphoma subtypes including Hodgkin lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma.

KW - Bone marrow

KW - Diffuse large B-cell lymphoma

KW - FDG-PET

KW - Follicular lymphoma

KW - Hodgkin lymphoma

UR - https://www.scopus.com/pages/publications/84948088882

U2 - 10.1016/j.blre.2015.06.003

DO - 10.1016/j.blre.2015.06.003

M3 - Article

C2 - 26113144

AN - SCOPUS:84948088882

SN - 0268-960X

VL - 29

SP - 417

EP - 425

JO - Blood Reviews

JF - Blood Reviews

IS - 6

ER -

Opportunities and limitations of bone marrow biopsy and bone marrow FDG-PET in lymphoma

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this